Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia

Othman, Noordin; Vitry, Agnes I.; Roughead, Elizabeth E.; Ismail, Shaiful B.; Omar, Khairani
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p743
Academic Journal
Background: Pharmaceutical representatives provide medicines information on their promoted products to doctors. However, studies have shown that the quality of this information is often low. No study has assessed the medicines information provided by pharmaceutical representatives to doctors in Malaysia and no recent evidence in Australia is present. We aimed to compare the provision of medicines information by pharmaceutical representatives to doctors in Australia and Malaysia. Methods: Following a pharmaceutical representative's visit, general practitioners in Australia and Malaysia who had agreed to participate, were asked to fill out a questionnaire on the main product and claims discussed during the encounter. The questionnaire focused on provision of product information including indications, adverse effects, precautions, contraindications and the provision of information on the Pharmaceutical Benefit Scheme (PBS) listings and restrictions (in Australia only). Descriptive statistics were produced. Chi-square analysis and clustered linear regression were used to assess differences in Australia and Malaysia. Results: Significantly more approved product information sheets were provided in Malaysia (78%) than in Australia (53%) (P < 0.001). In both countries, general practitioners reported that indications (Australia, 90%, Malaysia, 93%) and dosages (Australia, 76%, Malaysia, 82%) were frequently provided by pharmaceutical representatives. Contraindications, precautions, drug interactions and adverse effects were often omitted in the presentations (range 25% - 41%). General practitioners in Australia and Malaysia indicated that in more than 90% of presentations, pharmaceutical representatives partly or fully answered their questions on contraindications, precautions, drug interactions and adverse effects. More general practitioners in Malaysia (85%) than in Australia (60%) reported that pharmaceutical representatives should have mentioned contraindications, precautions for use, drug interaction or adverse effects spontaneously (P < 0.001). In 48% of the Australian presentations, general practitioners reported the pharmaceutical representatives failed to mention information on PBS listings to general practitioners. Conclusions: Information on indications and dosages were usually provided by pharmaceutical representatives in Australia and Malaysia. However, risk and harmful effects of medicines were often missing in their presentations. Effective control of medicines information provided by pharmaceutical representatives is needed.


Related Articles

  • SFINX—a drug-drug interaction database designed for clinical decision support systems. Böttiger, Ylva; Laine, Kari; Andersson, Marine; Korhonen, Tuomas; Molin, Björn; Ovesjö, Marie-Louise; Tirkkonen, Tuire; Rane, Anders; Gustafsson, Lars; Eiermann, Birgit // European Journal of Clinical Pharmacology;Jun2009, Vol. 65 Issue 6, p627 

    The aim was to develop a drug-drug interaction database (SFINX) to be integrated into decision support systems or to be used in website solutions for clinical evaluation of interactions. Key elements such as substance properties and names, drug formulations, text structures and references were...

  • THE BEST AND WORST DRUGS FOR WOMEN. Davis, Lisa; Burmeier, Beverly; von Bubnoff, Andreas // Prevention;Mar2007, Vol. 59 Issue 3, p167 

    This article explains that women are at increased risk for side effects from prescription drugs. The chemical make up of women contributes to the metabolizing of certain drugs. The author speaks of a gender based medicine where women are required to participate in all federally funded clinical...

  • Why Drug Safety Should Not Take a Back Seat to Efficacy.  // PLoS Medicine;Sep2011, Vol. 8 Issue 9, p1 

    The authors' reflect on the consideration given to the harmful effects from prescription drug use which can cause major adverse drug reactions and deaths. They refer to medical studies that suggest to improve the passive surveillance systems on drug safety concerns. However, the authors reveal...

  • Review of ADRs among kids in Finland.  // Reactions Weekly;10/20/2007, Issue 1174, p2 

    This article states that researchers in Finland have found out that majority of adverse drug interactions (ADRs) reported among children involve those aged 1-2 years and are caused by anti-infectives for systemic use. The Finnish National Agency for Medicines register has received a total of...

  • Anticoagulant AEs could halve with improved INR control.  // Reactions Weekly;6/2/2007, Issue 1154, p1 

    The article discusses research being done on the effect of improved anticoagulation control on the incidence of anticoagulant-associated adverse effects. It references a study by Oake et al published in the May 22, 2007 issue of the "Canadian Medical Association Journal." Results showed that...

  • Potential clinical relevant drug-drug interactions: comparison between different compendia, do we have a validated method? Conde-Estévez, D.; Echeverría-Esnal, D.; Tusquets, I.; Albanell, J.; van Leeuwen, R. W. F.; Mathijssen, R. H. J.; Jansman, F. G. A.; van Gelder, T. // Annals of Oncology;Jun2015, Vol. 26 Issue 6, p1272 

    No abstract available.

  • Oral targeted therapy for cancer. Carrington, Christine // Australian Prescriber;Oct2015, Vol. 38 Issue 5, p171 

    Oral targeted therapies are increasingly being used to treat cancer. They work by interfering with specific molecules or pathways involved in tumour growth. It is essential that health professionals managing patients taking these drugs have appropriate training and skills. They should be aware...

  • An Automated Standardized System for Managing Adverse Events in Clinical Research Networks. Richesson, Rachel L.; Malloy, Jamie F.; Paulus, Kathleen; Cuthbertson, David; Krischer, Jeffrey P. // Drug Safety;2008, Vol. 31 Issue 10, p807 

    Multi-site clinical protocols and clinical research networks require tools to manage and monitor adverse events (AEs). To be successful, these tools must be designed to comply with applicable regulatory requirements, reflect current data standards, international directives and advances in...

  • Drug interaction networks: an introduction to translational and clinical applications. Azuaje, Francisco // Cardiovascular Research;Mar2013, Vol. 97 Issue 4, p631 

    This article introduces fundamental concepts to guide the analysis and interpretation of drug–target interaction networks. An overview of the generation and integration of interaction networks is followed by key strategies for extracting biologically meaningful information. The article...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics